The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

The review extension was needed as the FDA required time to review Cytokinetics’ proposed Risk Evaluation and Mitigation Strategy (REMS).

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

Polycystic ovarian syndrome (PCOS) is a complex disorder of metabolism, endocrine function, and the reproductive system that affects an estimated 1 in 10 ...

Urcosimod is a lipid conjugated ChemR23 chemerin peptide agonist that is designed to reduce inflammation and pain in the eye.

The Food and Drug Administration (FDA) has cleared the Jewel ® Patch Wearable Cardioverter Defibrillator (Patch-WCD) for adult patients aged 18 years and older who are at risk for sudden cardiac ...